New Immunotherapy for Small Cell Lung Cancer Impresses in Phase II Clinical Trial

Karl Landsteiner University of Health Sciences important study center. Data published in New England Journal of Medicine.
By: KL Krems
KREMS, Austria - Nov. 23, 2023 - PRLog -- Results from a recently published phase II clinical trial of an immunotherapeutic agent (Tarlatamab) for the treatment of small cell lung cancer have demonstrated anti-tumor activity and a promising extension of overall survival in patients. The international study (DeLLphi-301) was conducted at 56 clinical centers in 17 countries. The University Hospital Krems of the Karl Landsteiner University of Health Sciences (KL Krems) played a particularly active role, treating numerous patients from Austria, Switzerland and the Czech Republic. Tarlatamab was evaluated as a possible treatment alternative for patients previously considered to be beyond treatment – and the results now available are promising in this respect.

Small cell lung carcinoma is a serious disease associated with poor survival. Although most patients respond to first- and second-line treatment, the disease usually progresses within a few months. However, options for subsequent third-line treatment are very limited as there are currently no approved drugs. The clinical evaluation of a new immunotherapeutic agent from Amgen Inc. offers hope. After a successful phase I trial, the results of the subsequent phase II trial were eagerly awaited – and have now been published in New England Journal of Medicine.

Original publication:

Scientific Contact

OA Dr. Sabin Handzhiev

Department of Pneumology

University Hospital Krems

Karl Landsteiner University of Health Sciences

Mitterweg 10

3500 Krems / Austria

T +43 2732 9004 12955



Copy Editing & Distribution

PR&D – Public Relations for Research & Education

Dr. Barbara Bauder

Kollersteig 68

3400 Klosterneuburg / Austria

M +43 664 1576 350



Source:KL Krems
Email:*** Email Verified
Tags:Lung Cancer
Location:Krems - Lower Austria - Austria
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
PR&D - Public Releations for Research & Education News
Most Viewed
Daily News

Like PRLog?
Click to Share